BioMedNewsBreaks — Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) Signs LOI to Acquire Quantum Cybersecurity Company Quantum.IQ

This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising. 

Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ)  announced it has entered into a non-binding letter of intent to explore the acquisition of Vancouver-based Quantum.IQ, an AI-driven quantum cybersecurity company focused on helping organizations prepare for emerging quantum-enabled cyber threats. Quantum.IQ’s post-quantum cryptography platform is designed to assist government, defense, financial services and critical infrastructure organizations in assessing cryptographic vulnerabilities, planning migration to quantum-resistant security systems and monitoring ongoing cybersecurity readiness.

Under the proposed transaction, Redwood would acquire all outstanding shares of Quantum.IQ in exchange for up to 14 million Redwood common shares, including milestone-based consideration, with all shares subject to a staged escrow release schedule over 24 months. The acquisition remains subject to due diligence, definitive agreements, regulatory approvals and other customary closing conditions. Redwood said the addition of Quantum.IQ could expand its capabilities in cryptographic intelligence, quantum-readiness assessment and cybersecurity planning, complementing its broader focus on artificial intelligence and advanced computational technologies.

To view the full press release, visit https://ibn.fm/hVVzl

About Redwood AI Corp.

Redwood AI uses advanced artificial intelligence to accelerate chemistry R&D, with the aim of assisting in drug discovery and development, and furthering defense and safety solutions. The Company combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up. Redwood AI’s platform is designed to enable faster, more efficient development of new therapies and chemistry-driven applications.

For more information go to https://redwoodai.com/

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN